Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Inclusion Criteria: * AD as defined by the American Academy of Dermatology Consensus Criteria. * History of AD for at least 12 months prior to baseline as determined by the Investigator through patient interview. * Eczema Area and Severity Index (EASI) score ≥ 12 at screening and at baseline. * IGA score ≥ 3 (on the 0 to 4 IGA scale) at baseline. * BSA of AD involvement ≥ 10% at baseline. * Documented inadequate response or intolerance to TCS within 6 months prior to baseline visit * Baseline PP-NRS score for maximum itch intensity ≥4. * All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * For optional substudy only: Willingness to have 2 tape strips for comparison of baseline and treatment response. Exclusion Criteria: * Skin comorbidities that may interfere with study assessments such as psoriasis, tinea corporis, lupus erythematosus. * Conditions that may predispose the patient to excessive bleeding. * Any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, trial evaluations, and/or trial procedures. * Laboratory abnormalities at the screening visit * History of serious infections requiring intravenous therapy with the potential for recurrence (as judged by the Site Investigator and the Sponsor Medical Monitor), with less than 4 weeks interval between resolut…